NCT00279721

Brief Summary

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2006

Typical duration for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

January 18, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 20, 2006

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

January 19, 2012

Status Verified

July 1, 2011

Enrollment Period

4.4 years

First QC Date

January 18, 2006

Last Update Submit

January 18, 2012

Conditions

Thyroid Neoplasms

Keywords

thyroid neoplasmsintensity modulated radiationradiotherapy

Outcome Measures

Primary Outcomes (2)

  • toxicity according to RTOG criteria

  • locoregional control

Interventions

IMRTPROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

You may not qualify if:

  • medullary or anaplastic thyroid cancer, unresectable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Officials

  • Harold Lau, MD

    Tom Baker Cancer Centre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 18, 2006

First Posted

January 20, 2006

Study Start

January 1, 2006

Primary Completion

June 1, 2010

Study Completion

June 1, 2010

Last Updated

January 19, 2012

Record last verified: 2011-07